title: The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects.
abstract: 1. Tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid) interacts stoichiometrically with haemoglobin to increase oxygen affinity. By decreasing the proportion of insoluble deoxy sickle haemoglobin at capillary oxygen concentrations, tucaresol may be of therapeutic benefit in sickle cell anaemia. 2. In this study, which involved the first administration to man, the pharmacokinetics and pharmacodynamics of tucaresol were studied in healthy male volunteers following oral doses of 200-3600 mg. 3. Peak drug concentrations in plasma and erythrocytes were linearly related to dose; mean (s.d.) values were 95.8 (26.1) and 1035 (67) micrograms ml-1, respectively, at the highest dose. Median tmax in plasma was 6.5 h and in erythrocytes 24.5 h, when approximately 60% of the administered dose was in the target tissue. Plasma drug concentrations fell biexponentially with commencement of the apparent terminal elimination phase at approximately 24 h. The terminal elimination half-life from plasma increased with dose (r = 0.77; P < 0.0001) from 133-190 h at 400 mg to a mean (s.d.) of 289 (30) h at 3600 mg. Erythrocyte drug concentrations declined mono-exponentially with a half-life that was always shorter than the apparent terminal half-life in plasma: overall mean (95% CI) of t1/2 erythrocyte/t1/2 plasma ratio was 0.57 (0.53, 0.61). The erythrocyte AUC/plasma AUC ratio increased with dose (r = 0.67; P < 0.001). 4. The proportion of haemoglobin modified to a form with high oxygen affinity (%MOD) increased in a dose-related manner above doses of 800 mg reaching 19-26% after the 3600 mg dose.(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Wellcome Research Laboratories, Beckenham, Kent.
authors: P E
authors: PE
authors: Rolan
authors: J E
authors: JE
authors: Parker
authors: S J
authors: SJ
authors: Gray
authors: B C
authors: BC
authors: Weatherley
authors: J
authors: J
authors: Ingram
authors: W
authors: W
authors: Leavens
authors: R
authors: R
authors: Wootton
authors: J
authors: J
authors: Posner
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000986:Antisickling Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001547:Benzaldehydes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001565:Benzoates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001772:Blood Cell Count / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008297:Male
chemical_list: D000986:Antisickling Agents; D001547:Benzaldehydes; D001565:Benzoates; D006454:Hemoglobins; C059629:tucaresol